EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients

Jianmei Huang, Chungyung Keung, Li Ma, Jingjing Zhao, Zhiqiang Xue, Shuxian Zhang, Yuan Chen, Lin Tao, Qingyang Liu, Cecilia Persson, Inna Prygova, Weimin Song

Aesthetic Surgery Journal Open Forum · 14.01.2026 · 8

DOI: 10.1093/asjof/ojag066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Surgery Journal Open Forum, online erschienen am 18.04.2026. Verfasst von Jianmei Huang und 11 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galderma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited.

Objectives

Primary objective: to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting. Secondary variables included effectiveness, patient and physician satisfaction in each cycle, and injection practice details.

Methods

In this non-interventional, multicenter study conducted in China, participants received 3 injection cycles of aboBoNT-A in the GL area, 3 to 6 months apart, with follow-up at Week 3, before the next treatment, and at end-of-study. Assessments included satisfaction questionnaires, GL wrinkle severity, and safety.

Results

At 3 weeks after the third injection, 100% of patients (N = 204) were satisfied with treatment (very satisfied: 71.1%; satisfied: 28.9%, primary endpoint), and physicians were very satisfied/satisfied with overall treatment outcome in 99.5% of patients. Physicians reported ≥1-grade improvement in GL severity at maximum frown in ≥90% of patients at 3 weeks in each cycle and in ≥64% at ∼5 months post-treatment (at next treatment). For ≥99% of patients, physicians would recommend aboBoNT-A to colleagues. The treatment was well tolerated, with no new safety findings.

Conclusions

All patients were satisfied with aboBoNT-A GL treatment after 3 injection cycles in this Chinese real-world study. As supported by multiple outcome measures, both patients and physicians reported high satisfaction with treatment and long-lasting improvement in wrinkle severity across single or repeat cycles. Treatment was well tolerated. Level of Evidence: 4 (Therapeutic) For image description, please refer to the figure legend and surrounding text.

Förderung

  • Galderma

Zitieren

APA

Huang, J., Keung, C., Ma, L., Zhao, J., Xue, Z., Zhang, S., Chen, Y., Tao, L., Liu, Q., Persson, C., Prygova, I., & Song, W. (2026). A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients. Aesthetic Surgery Journal Open Forum, 8. https://doi.org/10.1093/asjof/ojag066

Vancouver

Huang J, Keung C, Ma L, Zhao J, Xue Z, Zhang S, et al. A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients. Aesthetic Surgery Journal Open Forum. 2026;8. doi:10.1093/asjof/ojag066

BibTeX
@article{Huang2026,
  author = {Huang, Jianmei and Keung, Chungyung and Ma, Li and Zhao, Jingjing and Xue, Zhiqiang and Zhang, Shuxian and Chen, Yuan and Tao, Lin and Liu, Qingyang and Persson, Cecilia and Prygova, Inna and Song, Weimin},
  title = {A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients},
  journal = {Aesthetic Surgery Journal Open Forum},
  year = {2026},
  volume = {8},
  doi = {10.1093/asjof/ojag066}
}
Kostenlos starten →